Northwest Biotherapeutics, Inc. (NWBO)
0.1265
-0.01
(-8.99%)
USD |
OTCM |
Nov 20, 16:00
Northwest Biotherapeutics EPS Diluted (Quarterly) : -0.017 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.017 |
| June 30, 2026 | -0.0058 |
| March 31, 2026 | -0.0022 |
| December 31, 2025 | 0.0008 |
| September 30, 2025 | -0.0182 |
| June 30, 2025 | -0.0111 |
| March 31, 2025 | -0.0144 |
| December 31, 2024 | -0.0221 |
| September 30, 2024 | -0.0155 |
| June 30, 2024 | -0.0151 |
| March 31, 2024 | -0.0159 |
| December 31, 2023 | -0.0167 |
| September 30, 2023 | -0.0168 |
| June 30, 2023 | -0.0135 |
| March 31, 2023 | -0.0103 |
| December 31, 2022 | -0.0265 |
| September 30, 2022 | -0.0316 |
| June 30, 2022 | -0.0296 |
| March 31, 2022 | -0.0148 |
| December 31, 2021 | -0.0132 |
| September 30, 2021 | -0.0114 |
| June 30, 2021 | -0.0113 |
| March 31, 2021 | -0.0049 |
| December 31, 2020 | -0.3379 |
| September 30, 2020 | -0.2596 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.0832 |
| March 31, 2020 | 0.004 |
| December 31, 2019 | 0.0106 |
| September 30, 2019 | -0.011 |
| June 30, 2019 | 0.0004 |
| March 31, 2019 | -0.0396 |
| September 30, 2018 | 0.0163 |
| June 30, 2018 | -0.0582 |
| March 31, 2018 | -0.0887 |
| December 31, 2017 | -0.0859 |
| September 30, 2017 | -0.08 |
| June 30, 2017 | -0.05 |
| March 31, 2017 | -0.08 |
| December 31, 2016 | -0.25 |
| September 30, 2016 | -0.28 |
| June 30, 2016 | -0.16 |
| March 31, 2016 | -0.06 |
| December 31, 2015 | -0.27 |
| September 30, 2015 | 0.25 |
| June 30, 2015 | -0.88 |
| March 31, 2015 | -0.67 |
| December 31, 2014 | -0.65 |
| September 30, 2014 | -0.35 |
| June 30, 2014 | -0.45 |
| March 31, 2014 | -0.88 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1691 |
| Arrowhead Pharmaceuticals, Inc. | -3.029 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -28.76M |
| Revenue (Quarterly) | 0.883M |
| Total Expenses (Quarterly) | 29.64M |
| Enterprise Value | 308.73M |
| Gross Profit Margin (Quarterly) | -0.91% |
| Profit Margin (Quarterly) | -3.26K% |
| Earnings Yield | -19.13% |
| Normalized Earnings Yield | -25.30 |